title: Safety of infliximab in inflammatory bowel disease needs to be debated.
authors.forename: Hilbert S
authors.initials: HS
authors.lastname: de Vries
authors.forename: Martijn G H
authors.initials: MG
authors.lastname: Van Oijen
authors.forename: Dirk J
authors.initials: DJ
authors.lastname: de Jong
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D008875:Middle Aged; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D000069285:Infliximab